MCRB News & Events

Seres Therapeutics announced two transactions to extend its expected operating cash runway well into the first quarter of 2027. Seres entered into an amendment to the prior asset purchase agreement whereby Nestle Health Science will now pay Seres a total of $25M to buy out potential future Vowst net sales-based milestones, and a restructured lease agreement for one of Seres' locations which materially reduces the company's leased space and ongoing annual facility cash costs and long-term lease obligations. Seres previously developed Vowst, the first orally administered microbiome-based therapeutic approved by the FDA for the prevention of recurrence of Clostridioides difficile infection in adults following antibacterial treatment for recurrent CDI. Seres sold the Vowst business to Nestle Health Science in 2024. As of March 31, Seres had $29.8M in cash and cash equivalents. Based on the transactions described herein and current operating plans, Seres expects to fund operations well into the first quarter of 2027. This projection excludes proceeds from any potential future partnerships or other sources of capital. Seres sold its interest in the Vowst business to Nestle Health Science in 2024. Seres has entered into an amendment to the asset purchase agreement whereby Nestle Health Science will pay Seres an aggregate of $25M, in two installments of $12.5M each on July 1 and October 1 to buy-out the potential future milestones due to Seres if and upon the achievement of certain Vowst net sales targets. Seres has amended its lease with its landlord for the company's facility at 101 CambridgePark Drive in Cambridge, Massachusetts, reducing its leased space, rental rate and facility operating expenses. Under the amended arrangement, Seres will lease the retained space for a 10-year term at market-adjusted annual rent and a lower percentage of shared operating expenses for the building as of May 1 in exchange for the landlord drawing the existing letter of credit, Seres payment of a termination fee and the establishment of a new letter of credit. The restructured lease is expected to materially reduce the company's ongoing annual facility-related costs and long-term obligations. Additional details regarding the Nestle Health Science asset purchase agreement amendment and the lease amendment are included in the company's current report on Form 8-K which will be filed with the Securities and Exchange Commission.

Seres Therapeutics announced three presentations at the 2026 European Society of Clinical Microbiology and Infectious Diseases, ESCMID, global congress, taking place April 17-21 in Munich, Germany. A poster presentation by Seres highlighted biomarker and clinical pharmacology data from the Company's Phase 1b study of SER-155, evaluating changes in gastrointestinal microbiome composition following administration in patients undergoing allogeneic hematopoietic cell transplantation. Data showed that administration of SER-155 induced a significant and durable shift in GI microbiome composition relative to placebo, characterized by high SER-155 species relative abundance. This shift is associated with improved GI epithelial barrier integrity that could reduce the likelihood of bacterial translocation from the GI to the bloodstream. In contrast, placebo-treated participants showed low abundance of SER-155 species and related Firmicutes, high abundance of Bacteroidetes, and a compromised GI epithelial barrier. These findings are consistent with the intended mechanisms of action of SER-155, including protection of the GI epithelial barrier, and align with previously reported clinical observation of reduced incidence of bloodstream infections in SER-155-treated patients following allo-HCT.

Reports FY25 revenue $789k. "As highlighted in our recent announcements, we are prioritizing our promising inflammatory and immunology biotherapeutics portfolio, including SER-603 for inflammatory bowel disease," said Richard Kender, Executive Chair and interim CEO of Seres. "We are on track to report clinical data from the fully enrolled investigator-sponsored study at Memorial Sloan Kettering Cancer Center evaluating SER-155 to treat immune checkpoint inhibitor-related enterocolitis in the second quarter of this year. This serious condition affects up to 50% of immune checkpoint-treated cancer patients, with rates varying based on cancer drug and treatment regimen, and represents a sizable therapeutic and commercial opportunity. Additionally, our SER-155 program for the prevention of serious bloodstream infections in patients undergoing allo-HSCT for blood cancer is Phase 2 ready, and we continue to seek funding to support further development."